Evolution Research Group | Endeavor Clinical Trials
Status and phase
Conditions
Treatments
About
This study will evaluate the safety, efficacy, and PK of low dose (750 mg) and high-dose (1250 mg) XG005 oral tablets compared with placebo in subjects undergoing bunionectomy. Subjects will be confined in the clinic from check-in through 72 hours post-surgery to monitor subject safety.
Full description
This is a multi-center, randomized, double-blind, parallel-group, placebo-controlled study. Eligible subjects will be randomized in a 1:1:1 ratio to receive either 750 mg XG005, 1250 mg XG005, or placebo, twice a day, post bunionectomy surgery in domiciled clinic. Subjects and all study staff performing study assessments will be blinded to treatment allocation. Subjects will be discharged at a reasonable hour of the day after the end of the 72-hour treatment period.There will be a Follow-up Visit on Day 15.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Main inclusion criteria:
Main exclusion criteria:
Primary purpose
Allocation
Interventional model
Masking
450 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Joey Chang
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal